According to Shiyao Innovation's announcement, Shiyao Group Jushi Biopharmaceutical Co., Ltd., a holding subsidiary of the company, received a down payment of 30 million US dollars from AstraZeneca on August 12, 2026. The actual payment amount must be deducted from bank fees. The down payment corresponds to the “Cooperation, Choice and Authorization Agreement” signed by the two parties on July 1, 2026. The two parties will cooperate to develop novel nucleic acid candidates with small interfering molecules for extra-hepatic delivery.

According to Shiyao Innovation's announcement, Shiyao Group Jushi Biopharmaceutical Co., Ltd., a holding subsidiary of the company, received a down payment of 30 million US dollars from AstraZeneca on August 12, 2026. The actual payment amount must be deducted from bank fees. The down payment corresponds to the “Cooperation, Choice and Authorization Agreement” signed by the two parties on July 1, 2026. The two parties will cooperate to develop novel nucleic acid candidates with small interfering molecules for extra-hepatic delivery.